Bright Minds Biosciences Inc.
NASDAQ Capital MarketTotal Valuation
Bright Minds Biosciences Inc. carries a market capitalization of 577.61M, placing it among publicly traded companies globally. Its enterprise value stands at 517.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 577.61M |
| Enterprise Value | 517.11M |
Share Statistics
Bright Minds Biosciences Inc. currently has 9.79M shares outstanding.
| Shares Outstanding | 9.79M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.74 |
| P/TBV Ratio | 2.68 |
| P/FCF Ratio | -41.68 |
| P/OCF Ratio | -41.68 |
Financial Position
Bright Minds Biosciences Inc. maintains a current ratio of 81.48, meaning it holds 81.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 81.48 |
| Quick Ratio | 81.10 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -15.46 |
| Return on Assets (ROA) | -14.83 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Bright Minds Biosciences Inc.'s stock has gained approximately 170.12704% over the past 52 weeks. The 50-day moving average sits at 82.68, while the 200-day moving average is 71.50.
| Beta (5Y) | N/A |
| 52-Week Price Change | 170.12704% |
| 50-Day Moving Average | 82.68 |
| 200-Day Moving Average | 71.50 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -31.11M, while operating income came in at -31.18M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -31.18M |
| Pretax Income | -27.35M |
| Net Income | -27.35M |
| EBITDA | -31.11M |
| EBIT | -31.18M |
| Earnings Per Share (EPS) | -3.36 |
Balance Sheet
Bright Minds Biosciences Inc. holds 309.69M in cash and equivalents against 82,130.00 in total debt, resulting in a net debt position of -309.69M. Total book value stands at 301.18M, with working capital of 308.46M providing operational flexibility.
| Cash & Cash Equivalents | 309.69M |
| Total Debt | 82,130.00 |
| Net Debt | -309.69M |
| Equity (Book Value) | 301.18M |
| Book Value Per Share | 36.98 |
| Working Capital | 308.46M |
Cash Flow
Bright Minds Biosciences Inc. produced -19.83M in operating cash flow over the past twelve months.
| Operating Cash Flow | -19.83M |
| Capital Expenditures | N/A |
| Free Cash Flow | -19.83M |
| FCF Per Share | -2.44 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -33.28 |
| FCF Yield | -2.40 |
Stock Splits
Bright Minds Biosciences Inc.'s most recent stock split took place on July 14, 2023 with a 5:1 split ratio.
| Last Split Date | 7/14/2023 |
| Split Ratio | 5:1 |
Scores
Bright Minds Biosciences Inc. posts an Altman Z-Score of 129.99, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 129.99 |